Anti-MUC1 Nanobody Can Redirect T-Body Cytotoxic Effector Function
- 1 April 2009
- journal article
- research article
- Published by Mary Ann Liebert Inc in Hybridoma
- Vol. 28 (2), 85-92
- https://doi.org/10.1089/hyb.2008.0079
Abstract
Chimeric antigen T cell receptors provide a good approach for adoptive immunotherapy of cancer, especially in the context of cancerous cells that fail to express major histocompatibility complex antigen and co-stimulatory molecules. Clinical applications of these receptors are limited, mostly due to the xenogenic origin of the antibodies, which cause immunogenic reactions. Nanobodies are the smallest fragments of antibodies that have great homology to human VH and low immunogenic potential. MUC1 is a highly attractive immunotherapeutic target owing to increased expression, altered glycosylation, and loss of polarity in more than 80% of human malignancies. We used anti-MUC1 nanobody as an antigen binding domain, CD28 and CD3ζ as signaling domains, and IgG3 as a spacer in a chimeric receptor construct. This construct was transfected to Jurkat cells. The transfected Jurkat cells were exposed to MUC1-positive MCF7 cells. Then we analyzed the secretion of IL2, proliferation of Jurkat cells, and death of MCF7 cells. These data revealed that the nanobody chimeric receptor can target tumor-associated antigen-positive cells. Regarding the efficient and specific function of nanobody chimeric receptor and non-immunogenic nature of nanobodies, these chimeric receptors might be used as promising candidates for clinical applications.Keywords
This publication has 30 references indexed in Scilit:
- The T-Body Approach: Redirecting T Cells with Antibody SpecificityPublished by Springer Science and Business Media LLC ,2008
- The ST6GalNAc-I Sialyltransferase Localizes throughout the Golgi and Is Responsible for the Synthesis of the Tumor-associated Sialyl-Tn O-Glycan in Human Breast CancerJournal of Biological Chemistry, 2006
- Supernatural T cells: genetic modification of T cells for cancer therapyNature Reviews Immunology, 2005
- Vaccine and antibody-directed T cell tumour immunotherapyBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2004
- Single domain camel antibodies: current statusReviews in Molecular Biotechnology, 2001
- A STAT-responsive Element in the Promoter of the Episialin/MUC1 Gene Is Involved in Its Overexpression in Carcinoma CellsOnline Journal of Public Health Informatics, 2001
- Single domain antibodies: comparison of camel VH and camelised human VH domainsJournal of Immunological Methods, 1999
- An 2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomasGlycobiology, 1999
- Multi-parameter flow cytometric quantitation of the expression of the tumor-associated antigen SM3 in normal and neoplastic ovarian tissues. A comparison with HMFG1 and HMFG2Cancer, 1991
- A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM‐3 is selectively exposed in a range of primary carcinomasInternational Journal of Cancer, 1989